SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is highly discussed due to recent analyst coverage underscoring its strategic importance as a premier U.S. uranium and rare earth producer, especially with its unique White Mesa Mill and efforts to establish a fully integrated domestic supply chain. The community anticipates further developments, focusing on the company's critical role in energy security, defense, and supporting the AI boom amidst market volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community members passionately debate the escalating conflict with Iran, with supporters touting Trump's decisive actions against the nation while critics express alarm over the war's instigation and its economic fallout, particularly surging oil prices.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is gaining significant attention following a bullish Citron Research report highlighting its leadership in protecting against emerging AI agent-driven cyber threats, fueling community discussion around its deeply undervalued status and potential for a rebound within the oversold cybersecurity sector.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is actively trending as discussions around Kraken gaining Federal Reserve payment access and political pressure for clearer crypto legislation highlight increasing institutional integration. Community sentiment remains sharply divided between those anticipating a significant breakout and others forecasting further declines amid broader market volatility.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating Israeli airstrikes on Iranian oil facilities spark widespread concern about global energy supply, fueling community debate over sustained oil price increases amid disruptions to the Strait of Hormuz.

Exodus Movement, Inc. develops blockchain asset investors platform to secure, exchange and manage wealth inside one application. The company was founded by Daniel Castagnoli and Jon Paul Richardson in 2015 and is headquartered in Omaha, NE.

Exodus Movement Inc - Ordinary Shares - Class A

Exodus Movement is gaining attention for its confirmed debt-free status and recent strategic moves, including new partnerships and expansion into stablecoin payments and Web3 services. The community is noting its strong positioning for growth as broader crypto sentiment improves and legislative clarity for digital assets advances.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amidst discussions of substantial institutional inflows into its recently launched spot ETFs, fueled by perceived regulatory clarity, while community sentiment remains split between bullish adoption expectations and skepticism regarding its utility and supply dynamics.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is generating significant buzz following robust Q4 earnings, its Revuforj drug being named 'Best New Drug,' and multiple analyst price target increases, which are intensifying community speculation around a potential acquisition, especially by partner Incyte, while anticipation builds for upcoming data presentations at the ASH conference.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending following record quarterly revenues, robust 2026 guidance, and a "Strong-Buy" upgrade, which is amplifying community excitement about Recorlev's market dominance after a competitor's Cushing's drug faced an FDA rejection, alongside the advancing multi-billion dollar potential of its XP-8121 pipeline.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing strong momentum driven by compelling NXC-201 Phase 2 data showing high complete response rates and a favorable safety profile in AL amyloidosis, which has recently garnered FDA Breakthrough Therapy Designation. The community is buzzing about increased institutional accumulation, the potential for a short squeeze, and strategic interest, especially as the company presents at upcoming industry conferences and anticipates an imminent enrollment update.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TD Asset Management Inc Sells 39,388 Shares of Enliven Therapeutics, Inc. $ELVN

TD Asset Management Inc lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 58.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday

Enliven Therapeutics (NASDAQ:ELVN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?

Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High - Should You Buy...

Enliven Therapeutics: Q4 Earnings Insights

Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock...

Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 1,230 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold...

Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) saw a large decline in short interest in January. As of January 30th, there was short interest totaling 7,870,182 shares, a decline of 14.1...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.44	--	--	N/A
Q4 '25	-$0.38	-$0.48	-24.68%	MISSED
Q3 '25	-$0.43	-$0.32	26.15%	BEAT
Q2 '25	-$0.54	-$0.49	8.72%	BEAT
Q1 '25	-$0.50	-$0.57	-13.66%	MISSED

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ELVN News

ELVNEnliven Therapeutics Inc